Our government plays a critical role in the health of our nation. It funds large-scale medical research projects, manages entitlement programs such as Medicare and Medicaid, and crafts laws that support and promote access to care. For these reasons and more, it’s important that our lawmakers understand the health needs of people living with eczema.
NEA has a three-pronged approach to advocacy:
- Raise awareness among members of Congress and within federal agencies on just how eczema affects the lives of those with the disease and their families;
- Press for policies and laws that ensure access to affordable, effective eczema treatments;
- Increase the amount of money allocated at the federal level on eczema research to better understand and treat this disease.
NEA 2018 Policy Priorities and Initiatives
Eczema is a serious inflammatory disease that has a significant impact on the lives of those dealing with the condition. This is known as “burden of disease.” NEA works to raise awareness with lawmakers about the realities of life with eczema including:
- Time spent each day managing or preventing symptoms;
- The effect of eczema symptoms on work or school performance;
- How eczema pain interferes with quality of life;
- The impact on individuals and families of disrupted sleep due to eczema;
- Comorbid conditions associated with eczema such as asthma, mental health issues and severe infections;
- The cost of eczema on the individual, families, employers and society.
Access to Care
We believe what treatment you use to manage your eczema is a decision that belongs to you and your health care provider – and to you two only.
NEA works to control health insurance cost-cutting measures that interfere with you and your doctor’s ability to make the best choices about your health. These include:
Also known as “fail first,” step therapy requires a patient to try and fail another (usually less expensive) drug before the insurer will cover the medication originally prescribed by the doctor.
NEA Policy Priority: Work with health insurance companies to amend step therapy requirements when the patient has already tried and failed the “step” drug, or the drug is not right for patient health either because of potential side effects or because the drug is ineffective for the patient’s type and severity of eczema.
Prior authorization requires your health care provider to get approval from your insurance company before prescribing a particular medication. This layer of administrative complexity adds an unnecessary burden on doctor office staff and slows down a patient’s ability access medication, delaying symptom relief.
NEA Policy Priority: Encourage legislation that requires insurers to use prior authorization processes which are standardized, easy-to-use and sensitive to the health needs of patients.
Scientific innovation has brought many new medications that are targeted and for many, effective in controlling disease symptoms. However, the cost of these “specialty drugs” are increasingly being passed on to patients by insurance companies in the form of higher co-payments. These higher out-of-pocket costs can make important, life-altering treatments out of reach for many people managing serious chronic diseases.
NEA Policy Priority: Advocate for the passage of state legislation that caps out-of-pocket costs (co-payments, coinsurance limits, and prepayment requirements) on specialty drugs.
Network adequacy refers to the size of a health insurer’s network of providers relative to the size of the insured population, and its ability to deliver covered benefits and services quickly and conveniently for policyholders. Most states have requirements in place but changes in federal and state law could erode patients access to the providers who manage their care.
NEA Policy Priority: Requiring insurers to maintain networks of providers which are sufficiently trained to meet the health care needs of their members impacted by eczema.
Download the NEA position statement on access to care issues affecting the eczema community.
In 2016, the federal government spent $1.11 on research per every citizen with eczema. Considering the significant impact of eczema on the individual, the community and the society as a whole, NEA’s 2017 research priorities call for:
- An increase in the dollar amount allocated (appropriated) to eczema research by Congress to the National Institutes of Health;
- Federal funding to government agencies such as the Centers for Disease Control to determine the burden of disease for eczema.